7 unknown, 4 terminated, 3 completed, 2 active not recruiting. 19 Phase 2, 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Unknown 7, Terminated 4, Completed 3, Active not recruiting 2, Recruiting 2, Not yet recruiting 1 |
| Phase 1 | 7 | Unknown 5, Terminated 2 |
Follow Pyloric Stenosis: new trials by email Literature Review of Pyloric Stenosis trials Research Report on Pyloric Stenosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS BV+R-CHP - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin | Phase 2 | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 25 | 2025-09-01 | 2025-09-30 |
| Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations Venetoclax, Azacitidine, Cytarabine - Early T Acute Lymphoblastic Leukemia, T-Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | yuejun Liu | 32 | 2025-04-01 | 2025-06-10 |
| Embryonal Tumor With Multilayered Rosettes Radiotherapy (RT), Chemotherapy Drug, Cancer - Physician's Choice, Non-Investigational Surgical Resection - Embryonal Tumor With Multilayered Rosettes, Embryonal Tumor With Multilayered Rosettes, Nos | Phase 2 | Recruiting | University of California, San Francisco | 70 | 2025-03-06 | 2026-06-29 |
| Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas ACALABRUTINIB, LISOCABTAGENE MARALEUCEL, Lymphodepleting chemotherapy - Refractory Aggressive B-cell Lymphomas, Refractory B-Cell Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | Patrick C. Johnson, MD | 28 | 2023-03-01 | 2026-01-29 |
| Selinexor in Combination With R-CHOP Followed by Selinexor Maintenance for Untreated EBV-positive DLBCL Patients Selinexor, R-CHOP Protocol - EBV-Positive Diffuse Large B-Cell Lymphoma, Nos | Phase 1 / Phase 2 | Unknown | Sun Yat-sen University | 54 | 2022-11-01 | 2023-12-14 |
| Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL) Plamotamab, Tafasitamab, Lenalidomide - Diffuse Large-cell B-cell Lymphoma | Phase 2 | Terminated | Xencor, Inc. | 3 | 2022-04-15 | 2024-04-30 |
| An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas Nanatinostat in combination with valganciclovir - Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS | Phase 2 | Terminated | Viracta Therapeutics, Inc. | 102 | 2021-05-28 | 2025-07-28 |
| Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL PD-1 Antibody, Lenalidomide - Non-GCB/ABC Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 30 | 2021-03-31 | 2021-03-15 |
| Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL Zanubrutinib, Tislelizumab - Primary Mediastinal Large B Cell Lymphoma, EBV-Positive DLBCL, Nos | Phase 2 | Unknown | Ruijin Hospital | 40 | 2021-01-01 | 2021-03-30 |
| Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL Camrelizumab, Apatinib - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 33 | 2020-07-23 | 2021-03-15 |
| Lenalidomide in Combination With CHOP in Patients With Untreated PTCL Lenalidomide, Cyclophosphamide, Doxorubicin - PTCL, NOS, AITL | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 91 | 2020-06-10 | 2020-06-16 |
| Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma Toripalimab, Rituximab, R-CHOP Protocol - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Huiqiang Huang | 140 | 2020-04-24 | 2022-04-14 |
| Sintilimab in Combination With R-CHOP in Patients With Treatment-naive EBV-positive DLBCL, NOS Sintilimab, Rituximab, Cyclophosphamide - EBV-Positive DLBCL, Nos | Phase 2 | Unknown | The First Affiliated Hospital with Nanjing Medical University | 55 | 2019-01-01 | 2019-11-29 |
| Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease Fexinidazole, Placebo Oral Tablet - Chagas' Disease (Chronic) Nos | Phase 2 | Completed | Drugs for Neglected Diseases | 45 | 2017-11-13 | 2020-09-23 |
| Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers enzalutamide - Androgen Receptor Positive, Locally Advanced Salivary Gland Carcinoma | Phase 2 | Active not recruiting | Alliance for Clinical Trials in Oncology | 46 | 2016-09-14 | 2026-10-07 |
| Autologous Hematopoietic Stem Cell Transplantation for Allogeneic Organ Transplant Tolerance Autologous Hematopoietic Stem Cell Transplant - Complication of Transplanted Organ, Nos | Phase 2 | Completed | Gary A Levy, O. Ont. MD. FRCP AGAF | 5 | 2015-12-01 | 2021-04-28 |
| Prophylactic Ethanol Lock Therapy (ELT) in Patients on Home Parenteral Nutrition Ethanol, Heparin Lock, Normal Saline - Catheter-related Bloodstream Infection (CRBSI) Nos, Bloodstream Infection Due to Central Venous Catheter | Phase 1 / Phase 2 | Terminated | Mayo Clinic | 39 | 2014-07-01 | 2017-12-12 |
| Multiple Ascending Dose of BMS-911543 BMS-911543 - Cancer | Phase 1 / Phase 2 | Terminated | Bristol-Myers Squibb | 98 | 2011-04-07 | 2019-07-31 |
| PoC in Rheumatoid Arthritis With Methotrexate BMS-582949, Placebo - Rheumatoid Arthritis, NOS | Phase 2 | Completed | Bristol-Myers Squibb | 121 | 2008-03-01 | 2015-10-12 |
Pyloric Stenosis, Hypertrophic (19) · Lymphoma, Large B-Cell, Diffuse (4) · Recurrence (2) · Adenocarcinoma (1) · Arthritis, Rheumatoid (1) · Autoimmune Diseases (1) · Bronchiolitis Obliterans Syndrome (1) · Chagas Disease (1) · Epstein-Barr Virus Infections (1) · Leukemia, Biphenotypic, Acute (1) · Lymphoma, B-Cell (1) · Neoplasms (1) · Neuroectodermal Tumors, Primitive (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Salivary Gland Neoplasms (1)
Digestive System Diseases (19) · Gastric Outlet Obstruction (19) · Gastrointestinal Diseases (19) · Stomach Diseases (19) · Immune System Diseases (8) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Hemic and Lymphatic Diseases (5) · Immunoproliferative Disorders (5) · Lymphatic Diseases (5) · Lymphoproliferative Disorders (5) · Lymphoma (4) · Lymphoma, Non-Hodgkin (4) · Lymphoma, B-Cell (3)
Cyclophosphamide (4) · Doxorubicin (3) · Lenalidomide (3) · Rituximab (3) · Vincristine (3) · Prednisolone (2) · R-CHOP protocol (2) · tislelizumab (2) · 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo(1,2-f)(1,2,4)triazine-6-carboxamide (1) · Azacitidine (1) · Blood Specimen Collection (1) · Cytarabine (1) · Drug Therapy (1) · Ethanol (1) · Exportin 1 Protein (1)
Huiqiang Huang (3) · The First Affiliated Hospital with Nanjing Medical University (3) · Bristol-Myers Squibb (2) · Alliance for Clinical Trials in Oncology (1) · Drugs for Neglected Diseases (1) · Gary A Levy, O. Ont. MD. FRCP AGAF (1) · Mayo Clinic (1) · Patrick C. Johnson, MD (1) · Ruijin Hospital (1) · Sun Yat-sen University (1) · University of California, San Francisco (1) · Viracta Therapeutics, Inc. (1) · Xencor, Inc. (1) · yuejun Liu (1)
China (9) · United States (8) · Spain (4) · France (3) · Australia (2) · Canada (2) · South Korea (2) · Taiwan (2) · Argentina (1) · Brazil (1) · Czechia (1) · Germany (1) · Israel (1) · Italy (1) · Malaysia (1)
Wei Xu, M.D., Ph.D. (2) · Alan Ho, MD (1) · Connor Johnson, MD (1) · Darrel P Cohen, MD, PhD (1) · Derek Hanson, MD (1) · Gary A Levy, MD FRCP AGAF (1) · Harold L Atkins, MD FRCP(C) (1) · Huiqiang Huang, Professor (1) · Michael Chiarella (1) · Ryan Hurt, MD, PhD (1) · Sabine Mueller, MD, PhD, MAS (1) · Weili Zhao, PhD, MD (1) · Yue-jun Liu (1)
PMID 28576557, PMID 34049362, PMID 35867947, PMID 37530631, PMID 38218194
2016 (1)